Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.

Aldo Filosa,Angela Vitrano,Paolo Rigano,Giuseppina Calvaruso,Rita Barone,Marcello Capra,Liana Cuccia,Francesco Gagliardotto,Lorella Pitrolo,Luciano Prossomariti,Maddalena Casale,Vincenzo Caruso,Calogera Gerardi,Saveria Campisi,Paolo Cianciulli,Michele Rizzo,Giuseppe D'Ascola,Angela Ciancio,Aurelio Maggio

Blood Cells, Molecules, and Diseases（2013）

引用 24|浏览147

暂无评分

摘要

Transfusion and iron chelation treatment have significantly reduced morbidity and improved survival of patients with thalassemia major. However, cardiac disease continues to be the most common cause of death.

查看译文

关键词

Thalassemia major,Left ventricular ejection fraction (LVEF),Deferiprone,Deferoxamine,Echocardiography,Chelation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要